In molecular docking of the synthesized compounds against AD‐related targets, it revealed that the generated compounds had superior binding affinities of −12.9 and −8.5 kcal/mol for Aβ and tau, respectively, compared to conventional approaches [182]. This evidence concerns the gene MAPT and Alzheimer disease.